butabarbital decreases outcomes of sufentanil SL by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Watch Carefully. Coadministration of CYP3A4 inducers may decrease sufentanil stages and efficacy, perhaps precipitating withdrawal syndrome in people that have designed physical dependence to sufentanil. Discontinuation of conco